Regenesis Biomedical Revenue and Competitors

Regenesis Biomedical's core technology is protected by two issued United States patents and numerous additional American and international patent filings. The basis of CPI technology involves triggering the natural cascade and sequence of growth factors involved in the repair and regeneration of soft tissue cells. The first application of CPI technology resulted in the development and regulatory approval of the Provant(R) Wound Closure System. Provant is a portable, easy-to-use, biomedical device, which is cleared by the FDA to treat post-surgical wounds. The company is targeting the $10 billion American wound care market including outpatient home care, as well as the long-term and acute care. Each year in the United States, about six to seven million patients suffer from various acute and chronic wounds, such as pressure, diabetic and venous ulcers, surgical incisions, amputations, burns and graft sites.